Skip to main content
SpringerLink
Log in

Evaluation and Medical Management of BPH and LUTS in Men

  • Chapter
  • First Online:
Urological Men’s Health

Part of the book series: Current Clinical Urology ((CCU))

  • 862 Accesses

Abstract

Lower urinary tract symptoms (LUTS) is a common diagnosis among the aging population. Symptoms are classified either obstructive (hesitancy, weak stream, straining, and prolonged voiding), irritative (frequency, urgency, nocturia, urge incontinence, and voiding small volumes), or postmicturation (postvoid dribble, incomplete emptying). Most patients present with a combination of these symptoms. Multiple etiologies may underlie these symptoms including benign prostatic hyperplasia (BPH), extrinsic compression, prior pelvic surgery, pelvic radiotherapy, urethral stricture, and medications. We discuss the natural history, management, and treatment of BPH-related LUTS with medical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roehrborn CG. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell’s urology. 9th ed. Amsterdam: Elsevier.

    Google Scholar 

  2. Oishi K, Boyle P, Barry M. Epidemiology and natural history of benign prostatic hyperplasia. In: Fourth international consultation on benign prostatic hyperplasia. Plymouth: Plymbridge Distributors Ltd; 1998. p. 23.

    Google Scholar 

  3. Girman CJ. Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology. 1998;51:8.

    Article  PubMed  CAS  Google Scholar 

  4. Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res. 2008;20 Suppl 3:S19.

    Article  PubMed  Google Scholar 

  5. Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol. 2007;51:1645.

    Article  PubMed  Google Scholar 

  6. Lieber MM, Jacobsen SJ, Roberts RO, et al. Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes. Prostate. 2001;49:208.

    Article  PubMed  CAS  Google Scholar 

  7. Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581.

    Article  PubMed  CAS  Google Scholar 

  8. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006; 354:557.

    Article  PubMed  CAS  Google Scholar 

  9. Forray C, Bard J, Wetzel J, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;1994:4.

    Google Scholar 

  10. Krane R, Olsson C. Phenoxybenzamine in neurogenic bladder dysfunction: I. A theory of micturition. J Urol. 1973;110:650.

    PubMed  CAS  Google Scholar 

  11. Nordling J, Meyhoff H, Hald T. Sympatholytic effect on striated urethral sphincter. Scand J Urol Nephrol. 1981;15:173.

    Article  PubMed  CAS  Google Scholar 

  12. McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am J Med. 2005;118:1331.

    Article  PubMed  Google Scholar 

  13. Kirby RS, Coppinger SW, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol. 1987;60:136.

    Article  PubMed  CAS  Google Scholar 

  14. Chapple CR, Christmas T, Milroy EJ. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. BJU Int. 1992;70:285.

    CAS  Google Scholar 

  15. Kirby RS, Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell’s urology. 9th ed. Amsterdam: Elsevier.

    Google Scholar 

  16. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992;148:1467.

    PubMed  CAS  Google Scholar 

  17. Chapple C, Carter P, Christmas T, et al. A three-month double-blind study of doxazosin as treatment for benign prostatic obstruction. BJU Int. 1994;74:50.

    Article  CAS  Google Scholar 

  18. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154:105.

    Article  PubMed  CAS  Google Scholar 

  19. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose–response multicenter study. J Urol. 1995;154:110.

    Article  PubMed  CAS  Google Scholar 

  20. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998; 51:892.

    Article  PubMed  CAS  Google Scholar 

  21. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998;160:1701.

    Article  PubMed  CAS  Google Scholar 

  22. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92:257.

    Article  PubMed  CAS  Google Scholar 

  23. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019.

    Article  PubMed  CAS  Google Scholar 

  24. Yamanishi T, Mizuno T, Tatsumiya K, et al. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558.

    PubMed  CAS  Google Scholar 

  25. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634.

    Article  PubMed  CAS  Google Scholar 

  26. Malloy BJ, Price DT, Price RR, et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol. 1998;160:937.

    Article  PubMed  CAS  Google Scholar 

  27. Garimella PS, Fink HA, Macdonald R, et al. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;CD007360.

    Google Scholar 

  28. Coffey D, Walsh P. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:461.

    PubMed  CAS  Google Scholar 

  29. Shapiro E. Embryologic development of the prostate. Urol Clin North Am. 1990;17:487.

    PubMed  CAS  Google Scholar 

  30. Cabot A. The question of castration for enlarged prostate. Ann Surg. 1896;24:265.

    Article  PubMed  CAS  Google Scholar 

  31. White J. The results of double castration in hypertrophy of the prostate. Ann Surg. 1895;22:1.

    Article  PubMed  CAS  Google Scholar 

  32. Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. J Urol. 1975; 114:564.

    PubMed  CAS  Google Scholar 

  33. Donkervoort T, Zinner NR, Sterling AM, et al. Megestrol acetate in treatment of benign prostatic hypertrophy. Urology. 1975;6:580.

    Article  PubMed  CAS  Google Scholar 

  34. Schroeder FH, Westerhof M, Bosch RJ, et al. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. Eur Urol. 1986;12:318.

    PubMed  CAS  Google Scholar 

  35. APG Committee. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2 Pt 1):530.

    Google Scholar 

  36. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327:1185.

    Article  PubMed  CAS  Google Scholar 

  37. Andersen J, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo controlled study. Urology. 1995;46:631.

    Article  PubMed  CAS  Google Scholar 

  38. Marberger M. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology. 1998;51:677.

    Article  PubMed  CAS  Google Scholar 

  39. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43:284.

    Article  PubMed  CAS  Google Scholar 

  40. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557.

    Article  PubMed  CAS  Google Scholar 

  41. Roehrborn CG, Lukkarinen O, Mark S, et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int. 2005;96:572.

    Article  PubMed  Google Scholar 

  42. Fenter TC, Davis EA, Shah MB, et al. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. Am J Manag Care. 2008;14:S154.

    PubMed  Google Scholar 

  43. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993;45:253.

    PubMed  CAS  Google Scholar 

  44. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319.

    Article  PubMed  CAS  Google Scholar 

  45. Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175:999.

    Article  PubMed  CAS  Google Scholar 

  46. Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, et al. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009;182:1442.

    Article  PubMed  Google Scholar 

  47. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96:1339.

    Article  PubMed  Google Scholar 

  48. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637.

    Article  PubMed  Google Scholar 

  49. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824.

    Article  PubMed  Google Scholar 

  50. Vallancien G, Emberton M, Harving N, et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169:2257.

    Article  PubMed  Google Scholar 

  51. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97 Suppl 2:23.

    Article  PubMed  Google Scholar 

  52. McVary KT, Rademaker A, Lloyd GL, et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174:1327.

    Article  PubMed  Google Scholar 

  53. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836.

    Article  PubMed  CAS  Google Scholar 

  54. Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med. 2006;3:662.

    Article  PubMed  CAS  Google Scholar 

  55. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009;56:727.

    Article  PubMed  CAS  Google Scholar 

  56. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387.

    Article  PubMed  CAS  Google Scholar 

  57. Becher E, Roehrborn CG, Siami P, et al. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis. 2009;12:369.

    Article  PubMed  CAS  Google Scholar 

  58. Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009;103:919.

    Article  PubMed  CAS  Google Scholar 

  59. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123.

    Article  PubMed  Google Scholar 

  60. Jeong YB, Kwon KS, Kim SD, et al. Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. Urology. 2009;73:802.

    Article  PubMed  Google Scholar 

  61. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273.

    Article  PubMed  Google Scholar 

  62. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253.

    Article  PubMed  CAS  Google Scholar 

  63. Blake-James BT, Rashidian A, Ikeda Y, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. 2007;99:85.

    Article  PubMed  CAS  Google Scholar 

  64. Kaplan S, Gonzalez R, Te A. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717.

    Article  PubMed  CAS  Google Scholar 

  65. Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228.

    Article  PubMed  CAS  Google Scholar 

  66. Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53:1236.

    Article  PubMed  CAS  Google Scholar 

  67. Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010;183:1092.

    Article  PubMed  CAS  Google Scholar 

  68. Tuncel A, Nalcacioglu V, Ener K, et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28:17.

    Article  PubMed  CAS  Google Scholar 

  69. Chung DE, Te AE, Staskin DR, et al. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010;75:1144.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Weill Cornell Medical Center, 525 East 68th Street, Suite F9W, 261, New York, NY, 10065, USA

    Bilal Chughtai MD

  2. Department of Urology, Weill-Cornell Medical College of Cornell University, New York, NY, USA

    Richard Lee MD

  3. Department of Urology, Mount Sinai School of Medicine, New York, NY, USA

    Matthew Hall MD, BS (Physician)

  4. Department of Urology, Weill Cornell Medical Center, Brady Prostate Center and Urodynamic Laboratory, New York Presbyterian-Cornell, 1300 York Avenue, F9 West, 261, New York, NY, 11030, USA

    Alexis E. Te MD

Authors
  1. Bilal Chughtai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Hall MD, BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexis E. Te MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexis E. Te MD .

Editor information

Editors and Affiliations

  1. The Glickman Urologic and, Kidney Institute, Department of Urology, Cleveland, 44195, Ohio, USA

    Daniel A. Shoskes

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chughtai, B., Lee, R., Hall, M., Te, A.E. (2012). Evaluation and Medical Management of BPH and LUTS in Men. In: Shoskes, D. (eds) Urological Men’s Health. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-900-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-900-6_6

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-899-3

  • Online ISBN: 978-1-61779-900-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation